Overview

Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma

Status:
Unknown status
Trial end date:
2021-04-03
Target enrollment:
Participant gender:
Summary
This is a phase III, non-blinded, blocked randomized clinical trial. The study is conducted on 62 newly diagnosed patients with brain glioblastoma multiforme and anaplastic astrocytoma referring to the oncology clinics during March 2018 and March 2019. The patients will be randomized to 6-cycle and 12-cycle adjuvant Temozolomide groups using block randomization method (1:1).
Phase:
Phase 3
Details
Lead Sponsor:
Mashhad University of Medical Sciences
Treatments:
Dacarbazine
Temozolomide